Browse Tag

AstraZeneca’s Calquence approved in the EU for the treatment of most common type of leukaemia in adults

AstraZeneca’s Calquence approved in the EU for the treatment of most common type of leukaemia in adults

4 mins read

The FINANCIAL —  AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was based on positive results from two Phase III clinical trials, ELEVATE-TN in patients with previously untreated CLL and ASCEND in patients with relapsed or refractory CLL.1,2 This follows a recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency in July 2020. Paolo Ghia, MD, Director, Strategic Research Program…

Read More »

AstraZeneca’s Calquence approved in the EU for the treatment of most common type of leukaemia in adults

4 mins read

The FINANCIAL —  AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. The approval by the European Commission was based on positive results from two Phase III…